Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research
Methods in Cell Biology · 2025
DOI: 10.1016/bs.mcb.2024.10.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Methods in Cell Biology, 2025. Verfasst von Sophia Stock und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany; Department of Medicine III, LMU U…. Hauptthemen laut MEDLINE: Retroviridae, Receptors, Chimeric Antigen, T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: European Research Council, Elitenetzwerk Bayern, Deutsche Krebshilfe.
Abstract (Originalsprache)
Treatment with autologous chimeric antigen receptor (CAR)-modified T cells can achieve outstanding clinical response rates in heavily pretreated patients with B and plasma cell malignancies. However, relapses occur, and they limit the efficacy of this promising treatment approach. The complex GMP-compliant production and high treatment costs cause that CAR T cells cannot yet be used in a broad population. Among others, CAR T cell therapy has evolved regarding vector design and manufacturing process. Optimal production of CAR T cells is not yet defined, far from being standardized. Quality, cellular composition and immunophenotype of the administered CAR T cells are influenced by the manufacturing protocol and therefore play a crucial role for therapeutic success. For the gene transfer, viral and non-viral strategies are available. Retrovirus-based protocols for CAR T cell production offer advantages in terms of stable gene integration, sufficient transduction efficiency, proven clinical success, and scalability. Here, we detail a retrovirus-based generation protocol of human CAR-modified T cells for experimental immunotherapeutic treatment of cancer cells. For the CAR generation, HEK-293-based packaging cell lines, CD3+ selection, CD3/CD28-coated bead-based activation and IL-2/IL-15-mediated expansion were used. This protocol can be applied for every possible CAR construct after being successfully transfected in HEK-293-based packaging cell lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany; German Cancer Consort…
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
- CHU de Québec-Université Laval Research Center (Oncology division), Université Laval Cancer Research Center, Québec, QC, Canada.
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, A Partnership Between the DKFZ Heidelberg and LMU…
Förderung
- European Research Council
- Elitenetzwerk Bayern
- Deutsche Krebshilfe
- Bayerische Forschungsstiftung
- Bundesministerium für Bildung und Forschung
- Else Kröner-Fresenius-Stiftung
- Fritz-Bender-Stiftung
- José Carreras Leukämie-Stiftung
Zitieren
APA
Stock, S., Fertig, L., Menkhoff, V. D., Strzalkowski, T., Caruso, M., & Kobold, S. (2025). Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research. Methods in Cell Biology. https://doi.org/10.1016/bs.mcb.2024.10.017
Vancouver
Stock S, Fertig L, Menkhoff VD, Strzalkowski T, Caruso M, Kobold S. Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research. Methods in Cell Biology. 2025. doi:10.1016/bs.mcb.2024.10.017
BibTeX
@article{Stock2025,
author = {Stock, Sophia and Fertig, Luisa and Menkhoff, Vivien Doreen and Strzalkowski, Thaddäus and Caruso, Manuel and Kobold, Sebastian},
title = {Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research},
journal = {Methods in Cell Biology},
year = {2025},
doi = {10.1016/bs.mcb.2024.10.017}
}
EUVIMED